{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T05:22:57Z","timestamp":1791868977226,"version":"4.3.4"},"reference-count":77,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2010,6,1]],"date-time":"2010-06-01T00:00:00Z","timestamp":1275350400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Critical Reviews in Oncology\/Hematology"],"published-print":{"date-parts":[[2010,6]]},"DOI":"10.1016\/j.critrevonc.2009.09.003","type":"journal-article","created":{"date-parts":[[2009,10,13]],"date-time":"2009-10-13T09:28:22Z","timestamp":1255426102000},"page":"156-162","source":"Crossref","is-referenced-by-count":36,"title":["Primary cutaneous marginal zone lymphoma"],"prefix":"10.1016","volume":"74","author":[{"given":"St\u00e9phane","family":"Dalle","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luc","family":"Thomas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brigitte","family":"Balme","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles","family":"Dumontet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine","family":"Thieblemont","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.critrevonc.2009.09.003_bib1","doi-asserted-by":"crossref","first-page":"1410","DOI":"10.1002\/1097-0142(19831015)52:8<1410::AID-CNCR2820520813>3.0.CO;2-3","article-title":"Malignant lymphoma of mucosa-associated lymphoid tissue. A distinctive type of B-cell lymphoma","volume":"52","author":"Isaacson","year":"1983","journal-title":"Cancer"},{"key":"10.1016\/j.critrevonc.2009.09.003_bib2","doi-asserted-by":"crossref","unstructured":"A clinical evaluation of the International Lymphoma Study Group classification of non-Hodgkin's lymphoma. The Non-Hodgkin's Lymphoma Classification Project. Blood 1997;89:3909\u201318.","DOI":"10.1182\/blood.V89.11.3909"},{"key":"10.1016\/j.critrevonc.2009.09.003_bib3","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1093\/ajcp\/96.6.738","article-title":"Diversity of organ site involvement among malignant lymphomas of mucosa-associated tissues","volume":"96","author":"Pelstring","year":"1991","journal-title":"Am J Clin Pathol"},{"key":"10.1016\/j.critrevonc.2009.09.003_bib4","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1097\/00000478-199608000-00010","article-title":"Marginal zone lymphoma (low-grade B-cell lymphoma of mucosa-associated lymphoid tissue type) of skin and subcutaneous tissue: a study of 15 patients","volume":"20","author":"Bailey","year":"1996","journal-title":"Am J Surg Pathol"},{"key":"10.1016\/j.critrevonc.2009.09.003_bib5","doi-asserted-by":"crossref","first-page":"3768","DOI":"10.1182\/blood-2004-09-3502","article-title":"WHO-EORTC classification for cutaneous lymphomas","volume":"105","author":"Willemze","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2009.09.003_bib6","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1111\/j.1365-2559.1993.tb00469.x","article-title":"Cutaneous immunocytomas: a clinicopathologic study of 26 cases","volume":"23","author":"Rijlaarsdam","year":"1993","journal-title":"Histopathology"},{"key":"10.1016\/j.critrevonc.2009.09.003_bib7","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1182\/blood.V99.3.800","article-title":"Primary cutaneous lymphomas: applicability of current classification schemes (European Organization for Research and Treatment of Cancer. World Health Organization) based on clinicopathologic features observed in a large group of patients","volume":"99","author":"Fink-Puches","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2009.09.003_bib8","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1038\/nri799","article-title":"Marginal-zone B cells","volume":"2","author":"Martin","year":"2002","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.critrevonc.2009.09.003_bib9","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1146\/annurev.immunol.23.021704.115728","article-title":"Marginal zone B cells","volume":"23","author":"Pillai","year":"2005","journal-title":"Annu Rev Immunol"},{"key":"10.1016\/j.critrevonc.2009.09.003_bib10","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1016\/S1074-7613(01)00129-7","article-title":"Marginal zone and B1 B cells unite in the early response against T-independent blood-borne particulate antigens","volume":"14","author":"Martin","year":"2001","journal-title":"Immunity"},{"key":"10.1016\/j.critrevonc.2009.09.003_bib11","doi-asserted-by":"crossref","first-page":"2789","DOI":"10.1002\/eji.200535446","article-title":"Splenic marginal zone B cells in humans: where do they mutate their Ig receptor?","volume":"35","author":"Weller","year":"2005","journal-title":"Eur J Immunol"},{"key":"10.1016\/j.critrevonc.2009.09.003_bib12","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1111\/j.1365-2796.2009.02083.x","article-title":"Infectious agents and lymphoma development: molecular and clinical aspects","volume":"265","author":"Ferreri","year":"2009","journal-title":"J Intern Med"},{"key":"10.1016\/j.critrevonc.2009.09.003_bib13","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1002\/(SICI)1099-1069(199909)17:3<107::AID-HON644>3.0.CO;2-R","article-title":"Positive serology for Lyme disease borrelias in primary cutaneous B-cell lymphoma: a study in 22 patients, is it a fortuitous finding?","volume":"17","author":"Jelic","year":"1999","journal-title":"Hematol Oncol"},{"key":"10.1016\/j.critrevonc.2009.09.003_bib14","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1046\/j.1365-2559.2000.01003.x","article-title":"Borrelia burgdorferi-associated cutaneous marginal zone lymphoma: a clinicopathological study of two cases illustrating the temporal progression of B. burgdorferi-associated B-cell proliferation in the skin","volume":"37","author":"Goodlad","year":"2000","journal-title":"Histopathology"},{"key":"10.1016\/j.critrevonc.2009.09.003_bib15","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1097\/00000478-200009000-00012","article-title":"Primary cutaneous B-cell lymphoma and Borrelia burgdorferi infection in patients from the Highlands of Scotland","volume":"24","author":"Goodlad","year":"2000","journal-title":"Am J Surg Pathol"},{"key":"10.1016\/j.critrevonc.2009.09.003_bib16","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1111\/j.1600-0560.1997.tb01318.x","article-title":"Infection by Borrelia burgdorferi and cutaneous B-cell lymphoma","volume":"24","author":"Cerroni","year":"1997","journal-title":"J Cutan Pathol"},{"key":"10.1016\/j.critrevonc.2009.09.003_bib17","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1016\/0190-9622(91)70088-J","article-title":"Borrelia burgdorferi-associated cutaneous B cell lymphoma: clinical and immunohistologic characterization of four cases","volume":"24","author":"Garbe","year":"1991","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.critrevonc.2009.09.003_bib18","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1097\/00000478-200305000-00017","article-title":"Borrelia-associated primary cutaneous MALT lymphoma in a nonendemic region","volume":"27","author":"de la Fouchardiere","year":"2003","journal-title":"Am J Surg Pathol"},{"key":"10.1016\/j.critrevonc.2009.09.003_bib19","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/S0046-8177(00)80233-6","article-title":"Eradication of Borrelia burgdorferi infection in primary marginal zone B-cell lymphoma of the skin","volume":"31","author":"Roggero","year":"2000","journal-title":"Hum Pathol"},{"key":"10.1016\/j.critrevonc.2009.09.003_bib20","doi-asserted-by":"crossref","first-page":"1639","DOI":"10.1016\/S0140-6736(03)14798-8","article-title":"Lyme borreliosis","volume":"362","author":"Stanek","year":"2003","journal-title":"Lancet"},{"key":"10.1016\/j.critrevonc.2009.09.003_bib21","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1111\/j.0303-6987.2003.00167.x","article-title":"Borrelia burgdorferi-associated lymphocytoma cutis: clinicopathologic, immunophenotypic, and molecular study of 106 cases","volume":"31","author":"Colli","year":"2004","journal-title":"J Cutan Pathol"},{"key":"10.1016\/j.critrevonc.2009.09.003_bib22","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1097\/00000478-200308000-00003","article-title":"Primary cutaneous marginal zone B-cell lymphoma: a molecular and clinicopathologic study of 24 Asian cases","volume":"27","author":"Li","year":"2003","journal-title":"Am J Surg Pathol"},{"key":"10.1016\/j.critrevonc.2009.09.003_bib23","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1034\/j.1600-0560.2001.281002.x","article-title":"Absence of Borrelia burgdorferi DNA in cutaneous B-cell lymphomas from the United States","volume":"28","author":"Wood","year":"2001","journal-title":"J Cutan Pathol"},{"key":"10.1016\/j.critrevonc.2009.09.003_bib24","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1159\/000106580","article-title":"Borrelia burgdorferi-associated primary cutaneous marginal-zone B-cell lymphoma: a case report","volume":"215","author":"Monari","year":"2007","journal-title":"Dermatology"},{"key":"10.1016\/j.critrevonc.2009.09.003_bib25","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1111\/j.1365-2141.2005.05904.x","article-title":"Analysis of immunoglobulin V genes suggests cutaneous marginal zone B-cell lymphomas recognise similar antigens","volume":"132","author":"Bahler","year":"2006","journal-title":"Br J Haematol"},{"key":"10.1016\/j.critrevonc.2009.09.003_bib26","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1016\/S0190-9622(97)80405-7","article-title":"Borrelia burgdorferi-associated primary cutaneous B cell lymphoma: complete clearing of skin lesions after antibiotic pulse therapy or intralesional injection of interferon alfa-2a","volume":"36","author":"Kutting","year":"1997","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.critrevonc.2009.09.003_bib27","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1016\/S0046-8177(03)00075-3","article-title":"Cutaneous lymphoid hyperplasia: a lymphoproliferative continuum with lymphomatous potential","volume":"34","author":"Nihal","year":"2003","journal-title":"Hum Pathol"},{"key":"10.1016\/j.critrevonc.2009.09.003_bib28","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1067\/mjd.2002.120475","article-title":"Borrelia burgdorferi-associated lymphocytoma cutis simulating a primary cutaneous large B-cell lymphoma","volume":"47","author":"Grange","year":"2002","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.critrevonc.2009.09.003_bib29","doi-asserted-by":"crossref","first-page":"3034","DOI":"10.1182\/blood-2005-09-3679","article-title":"Infection-associated lymphomas derived from marginal zone B cells: a model of antigen-driven lymphoproliferation","volume":"107","author":"Suarez","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2009.09.003_bib30","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1111\/j.0736-8046.2004.21500.x","article-title":"The spectrum of cutaneous lymphomas in patients less than 20 years of age","volume":"21","author":"Fink-Puches","year":"2004","journal-title":"Pediatr Dermatol"},{"key":"10.1016\/j.critrevonc.2009.09.003_bib31","doi-asserted-by":"crossref","first-page":"468","DOI":"10.2350\/06-01-0006.1","article-title":"Primary cutaneous marginal zone B-cell lymphoma of MALT type in a child","volume":"9","author":"Dargent","year":"2006","journal-title":"Pediatr Dev Pathol"},{"key":"10.1016\/j.critrevonc.2009.09.003_bib32","doi-asserted-by":"crossref","first-page":"1376","DOI":"10.1200\/JCO.2005.03.6285","article-title":"Prognostic factors in primary cutaneous B-cell lymphoma: the Italian Study Group for Cutaneous Lymphomas","volume":"24","author":"Zinzani","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.critrevonc.2009.09.003_bib33","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1016\/j.annder.2008.07.057","article-title":"Marginal zone B-cell lymphoma affecting the skin: histological and phenotypic study of 49 cases","volume":"135","author":"Bathelier","year":"2008","journal-title":"Ann Dermatol Venereol"},{"key":"10.1016\/j.critrevonc.2009.09.003_bib34","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1046\/j.1365-2133.2002.04961.x","article-title":"Primary cutaneous marginal zone B-cell lymphoma: a clinical, histopathological, immunophenotypic and molecular genetic study of 22 cases","volume":"147","author":"Servitje","year":"2002","journal-title":"Br J Dermatol"},{"issue":"Suppl.","key":"10.1016\/j.critrevonc.2009.09.003_bib35","first-page":"S38","article-title":"Primary cutaneous marginal zone B-cell lymphoma","volume":"125","author":"Cho-Vega","year":"2006","journal-title":"Am J Clin Pathol"},{"key":"10.1016\/j.critrevonc.2009.09.003_bib36","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1111\/j.1365-2133.2003.05649.x","article-title":"Bcl-2, Bcl-6 and CD10 expression in cutaneous B-cell lymphoma: further support for a follicle centre cell origin and differential diagnostic significance","volume":"149","author":"Hoefnagel","year":"2003","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.critrevonc.2009.09.003_bib37","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1097\/00000478-200106000-00004","article-title":"Cutaneous b-cell lymphomas of follicular and marginal zone types: use of Bcl-6, CD10, Bcl-2, and CD21 in differential diagnosis and classification","volume":"25","author":"de Leval","year":"2001","journal-title":"Am J Surg Pathol"},{"key":"10.1016\/j.critrevonc.2009.09.003_bib38","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1016\/j.humpath.2006.02.012","article-title":"Aberrant nuclear BCL10 expression and lack of t(11, 18)(q21, q21) in primary cutaneous marginal zone B-cell lymphoma","volume":"37","author":"Gallardo","year":"2006","journal-title":"Hum Pathol"},{"key":"10.1016\/j.critrevonc.2009.09.003_bib39","doi-asserted-by":"crossref","first-page":"3355","DOI":"10.1182\/blood-2008-01-132415","article-title":"The majority of cutaneous marginal zone B-cell lymphomas expresses class-switched immunoglobulins and develops in a T-helper type 2 inflammatory environment","volume":"112","author":"van Maldegem","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2009.09.003_bib40","doi-asserted-by":"crossref","first-page":"2335","DOI":"10.1182\/blood-2002-09-2963","article-title":"T(14, 18)(q32, q21) involving IGH and MALT1 is a frequent chromosomal aberration in MALT lymphoma","volume":"101","author":"Streubel","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2009.09.003_bib41","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1038\/sj.leu.2403644","article-title":"T(3, 14)(p14.1, q32) involving IGH and FOXP1 is a novel recurrent chromosomal aberration in MALT lymphoma","volume":"19","author":"Streubel","year":"2005","journal-title":"Leukemia"},{"key":"10.1016\/j.critrevonc.2009.09.003_bib42","article-title":"Primary cutaneous marginal zone B-cell lymphomas are targeted by aberrant somatic hypermutation","author":"Deutsch","year":"2008","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.critrevonc.2009.09.003_bib43","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1038\/nature06547","article-title":"Two levels of protection for the B cell genome during somatic hypermutation","volume":"451","author":"Liu","year":"2008","journal-title":"Nature"},{"key":"10.1016\/j.critrevonc.2009.09.003_bib44","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1038\/ng.2007.35","article-title":"AID is required for germinal center-derived lymphomagenesis","volume":"40","author":"Pasqualucci","year":"2008","journal-title":"Nat Genet"},{"key":"10.1016\/j.critrevonc.2009.09.003_bib45","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1038\/35085588","article-title":"Hypermutation of multiple proto-oncogenes in B-cell diffuse large-cell lymphomas","volume":"412","author":"Pasqualucci","year":"2001","journal-title":"Nature"},{"key":"10.1016\/j.critrevonc.2009.09.003_bib46","doi-asserted-by":"crossref","first-page":"1833","DOI":"10.1182\/blood-2002-11-3606","article-title":"Aberrant somatic hypermutation in multiple subtypes of AIDS-associated non-Hodgkin lymphoma","volume":"102","author":"Gaidano","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2009.09.003_bib47","doi-asserted-by":"crossref","first-page":"4926","DOI":"10.1182\/blood-2005-08-3443","article-title":"Primary cutaneous follicle center lymphoma and primary cutaneous large B-cell lymphoma, leg type, are both targeted by aberrant somatic hypermutation but demonstrate differential expression of AID","volume":"107","author":"Dijkman","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2009.09.003_bib48","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1111\/j.1365-2141.2005.05454.x","article-title":"Aberrant somatic hypermutation and expression of activation-induced cytidine deaminase mRNA in mediastinal large B-cell lymphoma","volume":"129","author":"Bodor","year":"2005","journal-title":"Br J Haematol"},{"key":"10.1016\/j.critrevonc.2009.09.003_bib49","doi-asserted-by":"crossref","first-page":"3500","DOI":"10.1182\/blood-2006-06-030494","article-title":"MALT lymphoma and extranodal diffuse large B-cell lymphoma are targeted by aberrant somatic hypermutation","volume":"109","author":"Deutsch","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2009.09.003_bib50","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1016\/j.leukres.2007.11.028","article-title":"Quantifying the role of aberrant somatic hypermutation in transformation of follicular lymphoma","volume":"32","author":"Halldorsdottir","year":"2008","journal-title":"Leuk Res"},{"key":"10.1016\/j.critrevonc.2009.09.003_bib51","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1002\/path.1426","article-title":"Infrequent somatic Fas mutations but no evidence of Bcl10 mutations or t(11, 18) in primary cutaneous MALT-type lymphoma","volume":"201","author":"Gronbaek","year":"2003","journal-title":"J Pathol"},{"key":"10.1016\/j.critrevonc.2009.09.003_bib52","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1111\/j.0022-202X.2004.22720.x","article-title":"Molecular cytogenetic analysis of chromosomal breakpoints in the IGH, MYC, BCL6, and MALT1 gene loci in primary cutaneous B-cell lymphomas","volume":"123","author":"Hallermann","year":"2004","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.critrevonc.2009.09.003_bib53","first-page":"ELT14","article-title":"Absence of MALT1 translocations in primary cutaneous marginal zone B-cell lymphoma","volume":"89","author":"Espinet","year":"2004","journal-title":"Haematologica"},{"key":"10.1016\/j.critrevonc.2009.09.003_bib54","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1634\/theoncologist.11-3-285","article-title":"Nongastric marginal-zone B-cell MALT lymphoma: prognostic value of disease dissemination","volume":"11","author":"Arcaini","year":"2006","journal-title":"Oncologist"},{"key":"10.1016\/j.critrevonc.2009.09.003_bib55","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1182\/blood.V95.3.802.003k19_802_806","article-title":"Mucosa-associated lymphoid tissue lymphoma is a disseminated disease in one third of 158 patients analyzed","volume":"95","author":"Thieblemont","year":"2000","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2009.09.003_bib56","doi-asserted-by":"crossref","first-page":"2489","DOI":"10.1182\/blood-2002-04-1279","article-title":"Nongastric marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue","volume":"101","author":"Zucca","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2009.09.003_bib57","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1182\/blood-2006-10-054601","article-title":"TNM classification system for primary cutaneous lymphomas other than mycosis fungoides and Sezary syndrome: a proposal of the International Society for Cutaneous Lymphomas (ISCL) and the Cutaneous Lymphoma Task Force of the European Organization of Research and Treatment of Cancer (EORTC)","volume":"110","author":"Kim","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2009.09.003_bib58","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1111\/j.1365-2133.2008.08659.x","article-title":"Asymptomatic bone marrow involvement in patients presenting with cutaneous marginal zone B-cell lymphoma","volume":"159","author":"Bathelier","year":"2008","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.critrevonc.2009.09.003_bib59","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1111\/j.1365-2141.2008.07159.x","article-title":"Results of bone marrow examination in 275 patients with histological features that suggest an indolent type of cutaneous B-cell lymphoma","volume":"142","author":"Senff","year":"2008","journal-title":"Br J Haematol"},{"key":"10.1016\/j.critrevonc.2009.09.003_bib60","doi-asserted-by":"crossref","first-page":"6415","DOI":"10.1200\/JCO.2005.05.018","article-title":"State-of-the-art therapeutics: marginal-zone lymphoma","volume":"23","author":"Bertoni","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.critrevonc.2009.09.003_bib61","doi-asserted-by":"crossref","first-page":"1370","DOI":"10.1200\/JCO.2005.02.9025","article-title":"Antibiotic treatment is not effective in patients infected with Helicobacter pylori suffering from extragastric MALT lymphoma","volume":"24","author":"Grunberger","year":"2006","journal-title":"J Clin Oncol"},{"issue":"Suppl. 1","key":"10.1016\/j.critrevonc.2009.09.003_bib62","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1111\/j.0303-6987.2006.00544.x","article-title":"Standard and new treatments in cutaneous B-cell lymphomas","volume":"33","author":"Dreno","year":"2006","journal-title":"J Cutan Pathol"},{"key":"10.1016\/j.critrevonc.2009.09.003_bib63","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1007\/s001050050005","article-title":"Therapy of primary cutaneous B-cell lymphomas","volume":"51","author":"Zenahlik","year":"2000","journal-title":"Hautarzt"},{"key":"10.1016\/j.critrevonc.2009.09.003_bib64","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1001\/archderm.141.9.1139","article-title":"Primary cutaneous marginal zone B-cell lymphoma: clinical and therapeutic features in 50 cases","volume":"141","author":"Hoefnagel","year":"2005","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.critrevonc.2009.09.003_bib65","doi-asserted-by":"crossref","first-page":"1600","DOI":"10.1182\/blood-2008-04-152850","article-title":"European Organization for Research and Treatment of Cancer and International Society for Cutaneous Lymphoma consensus recommendations for the management of cutaneous B-cell lymphomas","volume":"112","author":"Senff","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2009.09.003_bib66","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1007\/s11864-006-0014-9","article-title":"Management of marginal zone lymphomas","volume":"7","author":"Thieblemont","year":"2006","journal-title":"Curr Treat Options Oncol"},{"key":"10.1016\/j.critrevonc.2009.09.003_bib67","doi-asserted-by":"crossref","first-page":"1520","DOI":"10.1001\/archderm.143.12.1520","article-title":"Results of radiotherapy in 153 primary cutaneous B-Cell lymphomas classified according to the WHO-EORTC classification","volume":"143","author":"Senff","year":"2007","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.critrevonc.2009.09.003_bib68","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1080\/10428190500399698","article-title":"Intra-lesional low-dose interferon alpha2a therapy for primary cutaneous marginal zone B-cell lymphoma","volume":"47","author":"Cozzio","year":"2006","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.critrevonc.2009.09.003_bib69","doi-asserted-by":"crossref","first-page":"2741","DOI":"10.1182\/blood-2002-11-3496","article-title":"Clinical activity of rituximab in extranodal marginal zone B-cell lymphoma of MALT type","volume":"102","author":"Conconi","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2009.09.003_bib70","doi-asserted-by":"crossref","DOI":"10.1093\/annonc\/mdn636","article-title":"Rituximab monotherapy for primary cutaneous B-cell lymphoma: response and follow-up in 16 patients","author":"Valencak","year":"2008","journal-title":"Ann Oncol"},{"key":"10.1016\/j.critrevonc.2009.09.003_bib71","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1111\/j.1365-2133.2005.06659.x","article-title":"Systemic eight-cycle anti-CD20 monoclonal antibody (rituximab) therapy in primary cutaneous B-cell lymphomas\u2014an applicational observation","volume":"153","author":"Gellrich","year":"2005","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.critrevonc.2009.09.003_bib72","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1080\/000155501750376339","article-title":"Systemic therapy of primary cutaneous B-cell lymphoma, marginal zone type, with rituximab, a chimeric anti-CD20 monoclonal antibody","volume":"81","author":"Soda","year":"2001","journal-title":"Acta Derm Venereol"},{"key":"10.1016\/j.critrevonc.2009.09.003_bib73","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1111\/j.1600-0609.2006.00720.x","article-title":"Favorable outcome of primary cutaneous marginal zone lymphoma treated with intralesional rituximab","volume":"77","author":"Kyrtsonis","year":"2006","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.critrevonc.2009.09.003_bib74","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1111\/j.1365-2133.2006.07523.x","article-title":"Intralesional and intravenous treatment of cutaneous B-cell lymphomas with the monoclonal anti-CD20 antibody rituximab: report and follow-up of eight cases","volume":"155","author":"Kerl","year":"2006","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.critrevonc.2009.09.003_bib75","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1046\/j.1365-2133.2000.03471.x","article-title":"Primary cutaneous B-cell lymphoma: a clinical, histological, phenotypic and genotypic study of 21 cases","volume":"142","author":"Gronbaek","year":"2000","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.critrevonc.2009.09.003_bib76","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1002\/ajh.20019","article-title":"Cutaneous B-cell lymphoma: pathological spectrum and clinical outcome in 51 consecutive patients","volume":"75","author":"Sah","year":"2004","journal-title":"Am J Hematol"},{"key":"10.1016\/j.critrevonc.2009.09.003_bib77","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1111\/j.1440-0960.2004.00057.x","article-title":"Cutaneous B-cell lymphoma of nails, pinna and nose treated with chlorambucil","volume":"45","author":"Stanway","year":"2004","journal-title":"Aust J Dermatol"}],"container-title":["Critical Reviews in Oncology\/Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842809001802?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842809001802?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,5,23]],"date-time":"2020-05-23T00:36:57Z","timestamp":1590194217000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1040842809001802"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,6]]},"references-count":77,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2010,6]]}},"alternative-id":["S1040842809001802"],"URL":"https:\/\/doi.org\/10.1016\/j.critrevonc.2009.09.003","relation":{},"ISSN":["1040-8428"],"issn-type":[{"value":"1040-8428","type":"print"}],"subject":[],"published":{"date-parts":[[2010,6]]}}}